Calliditas Therapeutics AB provided preliminary revenue guidance for the full year 2023. Preliminary Total revenues reaching $110 million to $113 million for 2023, as a result of milestone payments and royalty income from the Nefecon franchise outside the US.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
206.4 SEK | +0.39% |
|
+0.39% | +62.39% |
07-05 | European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading | MT |
07-05 | Calliditas Therapeutics' Partner Launches Japanese Trial for IgA Nephropathy Treatment | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.39% | 1.05B | |
+34.09% | 10.31B | |
+40.41% | 5.23B | |
-15.24% | 4.62B | |
+11.62% | 3.52B | |
+26.25% | 2.31B | |
-38.78% | 1.78B | |
-44.54% | 1.69B | |
-0.50% | 1.64B | |
+0.26% | 1.59B |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- Calliditas Therapeutics AB Provides Preliminary Revenue Guidance for the Full Year 2023